Sensus Healthcare (NASDAQ:SRTS) Downgraded by B. Riley to “Neutral”

B. Riley lowered shares of Sensus Healthcare (NASDAQ:SRTS) from a buy rating to a neutral rating in a report released on Thursday, Briefing.com Automated Import reports. The brokerage currently has $5.50 price target on the stock, down from their prior price target of $14.00.

Several other equities research analysts also recently weighed in on the stock. HC Wainwright restated a buy rating and issued a $10.00 target price on shares of Sensus Healthcare in a research note on Thursday. Maxim Group set a $11.00 target price on shares of Sensus Healthcare and gave the company a buy rating in a research note on Friday, August 9th. ValuEngine downgraded shares of Sensus Healthcare from a buy rating to a hold rating in a research note on Thursday, October 17th. Finally, TheStreet upgraded shares of Sensus Healthcare from a d+ rating to a c- rating in a research note on Monday, August 26th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of Hold and an average target price of $8.30.

Shares of NASDAQ:SRTS traded down $0.21 during trading on Thursday, reaching $3.80. 73,900 shares of the company were exchanged, compared to its average volume of 31,014. The firm has a market capitalization of $93.54 million, a PE ratio of -27.14 and a beta of -0.41. Sensus Healthcare has a 12-month low of $3.71 and a 12-month high of $9.23. The business’s fifty day simple moving average is $5.73 and its 200-day simple moving average is $5.72.

Sensus Healthcare (NASDAQ:SRTS) last announced its earnings results on Wednesday, November 6th. The company reported ($0.04) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. The company had revenue of $5.84 million during the quarter, compared to the consensus estimate of $7.77 million. Sensus Healthcare had a negative net margin of 8.65% and a negative return on equity of 8.82%. On average, sell-side analysts expect that Sensus Healthcare will post -0.12 EPS for the current fiscal year.

Several large investors have recently bought and sold shares of SRTS. Wells Fargo & Company MN acquired a new stake in shares of Sensus Healthcare during the second quarter worth $30,000. Susquehanna International Group LLP lifted its stake in shares of Sensus Healthcare by 69.9% during the second quarter. Susquehanna International Group LLP now owns 27,492 shares of the company’s stock worth $152,000 after buying an additional 11,311 shares during the period. Essex Investment Management Co. LLC acquired a new stake in shares of Sensus Healthcare during the third quarter worth $540,000. BlackRock Inc. lifted its stake in shares of Sensus Healthcare by 40.7% during the second quarter. BlackRock Inc. now owns 103,643 shares of the company’s stock worth $574,000 after buying an additional 29,990 shares during the period. Finally, Heartland Advisors Inc. lifted its stake in shares of Sensus Healthcare by 150.0% during the second quarter. Heartland Advisors Inc. now owns 375,000 shares of the company’s stock worth $2,078,000 after buying an additional 225,000 shares during the period. Institutional investors and hedge funds own 9.95% of the company’s stock.

About Sensus Healthcare

Sensus Healthcare, Inc manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.

Featured Article: What does RSI mean?

Analyst Recommendations for Sensus Healthcare (NASDAQ:SRTS)

Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.